Arvinas Inc (ARVN)

$34.29

+0.84

(+2.51%)▲

Market is closed - opens 7 PM, 19 Apr 2024

Insights on Arvinas Inc

  • Decreasing Revenue

    Revenue is down for the last 3 quarters, 54.5M → -43.1M (in $), with an average decrease of 130.5% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, -64.0M → -154.8M (in $), with an average decrease of 141.9% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 46.7% return, outperforming this stock by 24.0%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 245.1% return, outperforming this stock by 293.4%

Performance

  • $32.61
    $34.46
    $34.29
    downward going graph

    4.9%

    Downside

    Day's Volatility :5.37%

    Upside

    0.49%

    downward going graph
  • $13.57
    $53.08
    $34.29
    downward going graph

    60.43%

    Downside

    52 Weeks Volatility :74.43%

    Upside

    35.4%

    downward going graph

Returns

PeriodArvinas IncSector (Health Care)Index (Russel 2000)
3 Months
-8.05%
-0.7%
0.0%
6 Months
117.49%
6.6%
0.0%
1 Year
22.71%
3.7%
-1.5%
3 Years
-46.2%
14.0%
-21.8%

Highlights

Market Capitalization
2.3B
Book Value
$9.71
Earnings Per Share (EPS)
-6.62
Wall Street Target Price
70.83
Profit Margin
0.0%
Operating Margin TTM
383.53%
Return On Assets TTM
-19.5%
Return On Equity TTM
-59.97%
Revenue TTM
78.5M
Revenue Per Share TTM
1.41
Quarterly Revenue Growth YOY
4.2%
Gross Profit TTM
131.4M
EBITDA
-396.7M
Diluted Eps TTM
-6.62
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-5.32
EPS Estimate Next Year
-5.62
EPS Estimate Current Quarter
-1.27
EPS Estimate Next Quarter
-1.4

Analyst Recommendation

Buy
    80%Buy
    19%Hold
    0
    0%Sell
Based on 26 Wall street analysts offering stock ratings for Arvinas Inc(by analysts ranked 0 to 5 stars)
Based on 26 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
21
20
21
Hold
5
6
6
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 106.56%

Current $34.29
Target $70.83

Company Financials

FY18Y/Y Change
Revenue
14.3M
↑ 89.0%
Net Income
-41.5M
↑ 72.48%
Net Profit Margin
-289.59%
↑ 27.73%
FY19Y/Y Change
Revenue
43.0M
↑ 200.03%
Net Income
-62.1M
↑ 49.79%
Net Profit Margin
-144.57%
↑ 145.02%
FY20Y/Y Change
Revenue
21.8M
↓ 49.27%
Net Income
-111.8M
↑ 79.92%
Net Profit Margin
-512.74%
↓ 368.17%
FY21Y/Y Change
Revenue
46.7M
↑ 114.2%
Net Income
-183.2M
↑ 63.88%
Net Profit Margin
-392.29%
↑ 120.45%
FY22Y/Y Change
Revenue
131.4M
↑ 181.37%
Net Income
-271.9M
↑ 48.42%
Net Profit Margin
-206.93%
↑ 185.36%
FY23Y/Y Change
Revenue
78.5M
↓ 40.26%
Net Income
-367.3M
↑ 35.09%
Net Profit Margin
-467.9%
↓ 260.97%
Q3 FY22Q/Q Change
Revenue
30.3M
↓ 3.19%
Net Income
-66.2M
↓ 5.43%
Net Profit Margin
-218.48%
↑ 5.16%
Q4 FY22Q/Q Change
Revenue
38.0M
↑ 25.41%
Net Income
-79.9M
↑ 20.69%
Net Profit Margin
-210.26%
↑ 8.22%
Q1 FY23Q/Q Change
Revenue
32.5M
↓ 14.47%
Net Income
-80.8M
↑ 1.13%
Net Profit Margin
-248.62%
↓ 38.36%
Q2 FY23Q/Q Change
Revenue
54.5M
↑ 67.69%
Net Income
-66.6M
↓ 17.57%
Net Profit Margin
-122.2%
↑ 126.42%
Q3 FY23Q/Q Change
Revenue
34.6M
↓ 36.51%
Net Income
-64.0M
↓ 3.9%
Net Profit Margin
-184.97%
↓ 62.77%
Q4 FY23Q/Q Change
Revenue
-43.1M
↓ 224.57%
Net Income
-154.8M
↑ 141.88%
Net Profit Margin
359.16%
↑ 544.13%
FY18Y/Y Change
Total Assets
199.3M
↑ 198.11%
Total Liabilities
62.6M
↓ 5.99%
FY19Y/Y Change
Total Assets
301.6M
↑ 51.36%
Total Liabilities
75.0M
↑ 19.71%
FY20Y/Y Change
Total Assets
717.4M
↑ 137.82%
Total Liabilities
75.1M
↑ 0.21%
FY21Y/Y Change
Total Assets
1.6B
↑ 120.47%
Total Liabilities
799.9M
↑ 964.96%
FY22Y/Y Change
Total Assets
1.3B
↓ 19.78%
Total Liabilities
703.9M
↓ 12.0%
FY23Y/Y Change
Total Assets
1.3B
↑ 2.82%
Total Liabilities
644.6M
↓ 8.42%
Q3 FY22Q/Q Change
Total Assets
1.3B
↓ 5.13%
Total Liabilities
713.3M
↓ 3.14%
Q4 FY22Q/Q Change
Total Assets
1.3B
↓ 4.94%
Total Liabilities
703.9M
↓ 1.32%
Q1 FY23Q/Q Change
Total Assets
1.2B
↓ 7.33%
Total Liabilities
664.8M
↓ 5.55%
Q2 FY23Q/Q Change
Total Assets
1.1B
↓ 7.85%
Total Liabilities
619.9M
↓ 6.75%
Q3 FY23Q/Q Change
Total Assets
1.1B
↓ 2.33%
Total Liabilities
601.1M
↓ 3.03%
Q4 FY23Q/Q Change
Total Assets
1.3B
↑ 23.27%
Total Liabilities
644.6M
↑ 7.24%
FY18Y/Y Change
Operating Cash Flow
-16.1M
↓ 415.22%
Investing Cash Flow
-179.7M
↓ 960.79%
Financing Cash Flow
168.1M
↓ 104250.7%
FY19Y/Y Change
Operating Cash Flow
-40.6M
↑ 152.06%
Investing Cash Flow
-93.1M
↓ 48.18%
Financing Cash Flow
139.7M
↓ 16.85%
FY20Y/Y Change
Operating Cash Flow
-89.8M
↑ 120.93%
Investing Cash Flow
164.3M
↓ 276.43%
Financing Cash Flow
504.7M
↑ 261.14%
FY21Y/Y Change
Operating Cash Flow
559.4M
↓ 723.24%
Investing Cash Flow
-1.3B
↓ 899.76%
Financing Cash Flow
278.6M
↓ 44.8%
FY22Y/Y Change
Operating Cash Flow
-273.5M
↓ 148.89%
Investing Cash Flow
242.8M
↓ 118.48%
Financing Cash Flow
4.7M
↓ 98.31%
Q3 FY22Q/Q Change
Operating Cash Flow
-66.6M
↓ 15.27%
Investing Cash Flow
105.8M
↓ 2.94%
Financing Cash Flow
1.2M
↑ 140.0%
Q4 FY22Q/Q Change
Operating Cash Flow
-71.2M
↑ 6.91%
Investing Cash Flow
19.4M
↓ 81.66%
Financing Cash Flow
500.0K
↓ 58.33%
Q1 FY23Q/Q Change
Operating Cash Flow
-91.2M
↑ 28.09%
Investing Cash Flow
138.6M
↑ 614.43%
Financing Cash Flow
1.5M
↑ 200.0%
Q2 FY23Q/Q Change
Operating Cash Flow
-88.7M
↓ 2.74%
Investing Cash Flow
48.6M
↓ 64.94%
Financing Cash Flow
500.0K
↓ 66.67%

Technicals Summary

Sell

Neutral

Buy

Arvinas Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Arvinas Inc
Arvinas Inc
-21.48%
117.49%
22.71%
-46.2%
46.45%
Moderna, Inc.
Moderna, Inc.
-0.79%
20.27%
-27.48%
-36.11%
359.53%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-6.12%
9.1%
11.53%
80.35%
170.35%
Novo Nordisk A/s
Novo Nordisk A/s
-6.29%
23.82%
46.7%
242.59%
414.69%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-4.44%
6.95%
20.9%
79.35%
133.77%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Arvinas Inc
Arvinas Inc
NA
NA
NA
-5.32
-0.6
-0.19
NA
9.71
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.22
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
25.71
25.71
1.46
45.13
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
46.58
46.58
2.4
3.33
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.42
28.42
0.53
16.73
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Arvinas Inc
Arvinas Inc
Buy
$2.3B
46.45%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$39.8B
359.53%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$98.1B
170.35%
25.71
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$551.2B
414.69%
46.58
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$101.9B
133.77%
28.42
36.68%

Institutional Holdings

  • EcoR1 Capital, LLC

    9.88%

  • BlackRock Inc

    7.87%

  • Vanguard Group Inc

    7.13%

  • RTW INVESTMENTS, LLC

    6.19%

  • T. Rowe Price Associates, Inc.

    5.63%

  • Avidity Partners Management LP

    4.38%

Corporate Announcements

  • Arvinas Inc Earnings

    Arvinas Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

arvinas is a pharmaceutical company focused on developing new small molecules ‒ known as protacs (proteolysis targeting chimeras) ‒ aimed at degrading disease-causing cellular proteins via proteolysis. based on innovative research conducted at yale university by dr. craig crews, founder and chief scientific advisor, the company is translating natural protein degradation approaches into novel drugs for the treatment of cancer and other diseases. the proprietary protac-based drug paradigm induces protein degradation, rather than protein inhibition, using the ubiquitin proteasome system and offers the advantage of potentially targeting “undruggable” as well as “druggable” elements of the proteome. this greatly expands the ability to create drugs for many new, previously unapproachable targets. for more information, visit www.arvinas.com.

Organization
Arvinas Inc
Employees
445
CEO
Dr. John G. Houston Ph.D.
Industry
Health Technology

Discover More

FAQs